Dendreon Reschedules Third Quarter 2012 Results to November 2 Due to Hurricane Sandy

  Dendreon Reschedules Third Quarter 2012 Results to November 2 Due to
  Hurricane Sandy

Business Wire

SEATTLE -- October 29, 2012

October 29, 2012–Dendreon Corporation (Nasdaq: DNDN) today announced that in
light of Hurricane Sandy, the Company has rescheduled the release of its third
quarter 2012 earnings results. Certain members of its senior management team
and commercial operations are in the Company’s Bridgewater, New Jersey office,
where the call was expected to originate. Dendreon will now be releasing its
financial results on Friday, November 2, 2012, and will hold the related
investor conference call the same day at 9:00 a.m. ET. The Company had
previously planned to announce its third quarter 2012 earnings on October 30,
2012.

Conference Call Information

Dendreonwill host a conference call onNovember 2, 2012at9:00 a.m. ET. To
access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037
(international); the conference ID number is 38408702. The call will also be
audio webcast with supplemental information slides available from the
Company's website at http://www.dendreon.comunder the “Investor/Webcasts and
Presentations” section. A recorded rebroadcast will be available for
interested parties unable to participate in the live conference call by
dialing 1- 800-585-8367 or +1-404-537-3406 for international callers; the
conference ID number is 38408702. The replay will be available from 12:00 p.m.
ET on Friday, November 2, until 11:59 p.m. ET on Friday, November 9. In
addition, the webcast will be archived for on-demand listening for 90 days at
www.dendreon.com and the supplemental information slides will be posted to the
Company’s website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon’s first
product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington, and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
http://www.dendreon.com/.

Contact:

Dendreon Corporation
Nicole Soley
Investor Relations
206-455-2220
InvestorRelations@dendreon.com